ELUT vs ABT

For growth investors, Abbott Laboratories (ABT) is the stronger pick with 4.

6% revenue growth year-over-year, versus -49. 6% for Elutia Inc. (ELUT). Elutia Inc. (ELUT) offers the better valuation at 0. 8x trailing P/E, making it the more compelling value choice. Analysts rate Abbott Laboratories (ABT) a "Buy" — based on 41 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Elutia Inc.

(ELUT) is the cheapest at 0. 8x versus Abbott Laboratories at 11. 4x.

Over the past 5 years, Abbott Laboratories (ABT) delivered a total return of -17.

9%, compared to -91. 4% for Elutia Inc. (ELUT). Over 10 years, the gap is even starker: ABT returned +173. 7% versus ELUT's -93. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Elutia Inc.

(ELUT) is the lower-risk stock at -0. 11β versus Abbott Laboratories's 0. 25β — meaning ABT is approximately -333% more volatile than ELUT relative to the S&P 500. On balance sheet safety, Elutia Inc. (ELUT) carries a lower debt/equity ratio of 27% versus 32% for Abbott Laboratories — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Abbott Laboratories (ABT) is pulling ahead at 4.

6% versus -49. 6% for Elutia Inc. (ELUT). On earnings-per-share growth, the picture is similar: Elutia Inc. grew EPS 169. 4% year-over-year, compared to 133. 6% for Abbott Laboratories. Over a 3-year CAGR, ABT leads at -0. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Elutia Inc.

(ELUT) is the more profitable company, earning 434. 2% net margin versus 31. 9% for Abbott Laboratories — meaning it keeps 434. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ABT leads at 16. 3% versus -149. 8% for ELUT. At the gross margin level — before operating expenses — ELUT leads at 53. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, ABT (2.

5% yield) pays a dividend. ELUT does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Abbott Laboratories (ABT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

25), 2. 5% yield, +173. 7% 10Y return). Both have compounded well over 10 years (ABT: +173. 7%, ELUT: -93. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

ABT pays a dividend while ELUT does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.